New Antiviral Option for CMV Prophylaxis After Kidney Transplant

(MedPage Today) -- Letermovir (Prevymis) proved noninferior to valganciclovir (Valcyte), the standard of care, in a clinical trial of cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients, researchers reported. In a phase III...
Source: MedPage Today Surgery - Category: Surgery Source Type: news